FENNEC PHARMACEUTICALS INC. FENC Income Statement

Fennec pharmaceuticals inc. (FENC)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Revenue
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating expenses:
Research and development
5,329	5,607	6,158	7,161	5,990	5,008	4,171	2,865	2,400	1,936	1,224	844	650	472	369	345	260	256	273	257	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development Sodium Thiosulfate
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	443	597	1,070	1,651	1,957	2,075	2,019	2,101	1,475	1,494	1,098	805	0	0	0
Impairment of capital assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Gain on deferred lease inducements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Research and development Eniluracil
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	0	0	0	0	0	0	0	0	-	-
General and administrative
8,835	7,402	6,303	6,285	5,308	5,401	5,648	6,292	5,571	5,015	4,358	3,116	2,538	2,399	1,907	1,705	1,632	1,634	1,780	2,061	2,424	2,520	2,221	1,965	1,480	1,334	1,569	1,567	1,584	1,545	1,378	1,610	1,558	1,944	2,356	4,210	0	0	0
Total operating expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	0	0
Loss from operations
-14,164	-13,009	-12,461	-13,446	-11,298	-10,409	-9,819	-9,157	-7,971	-6,951	-5,582	-3,960	-3,188	-2,871	-2,276	-2,050	-1,892	-1,890	-2,130	-2,411	-2,792	-2,877	-2,502	-1,934	-1,931	-1,931	-2,639	-3,218	-3,541	-3,620	-3,397	-3,711	-3,033	-3,438	-3,454	-5,015	0	0	0
Other (expense) income :
Sale of Eniluracil (Note 8)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized/realized gain on derivatives
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-
Other (loss)
-26	-17	-3	-6	9	6	-4	-1	-10	-8	-6	-7	-6	-14	0	-24	0	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-
Unrealized gain/(loss) on derivatives (Note 5)
-	-	0	0	-	167	373	190	70	-134	-337	-135	-32	48	56	253	655	1,237	3,436	3,839	3,635	355	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization expense
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	0	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement of Cadherin litigation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	-	-
Gain on derivative settlement (Note 5)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	-3,142	-1,573	-8,463	-1,563	1,612	1,976	0	-	0	0	-	0	0
Other (loss)/gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-6	1	-1	-5	-4	-4	0	-	0	0	-	0	-
Gain on derivative settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Interest income and other
284	315	361	392	355	348	256	171	103	47	26	13	11	8	0	5	0	-	0	0	-	2	4	4	-2	2	8	13	19	25	29	45	41	43	43	30	0	0	0
(Loss)/gain on currency exchange and other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income, net
189	234	312	357	352	521	625	360	163	-95	-317	-89	13	82	90	243	636	1,231	3,399	4,183	3,987	701	50	-2,664	4,690	3,776	-3,140	-1,559	-8,445	-1,543	8,254	6,188	5,764	8,123	6,325	8,461	0	0	0
Net loss
-13,975	-12,775	-12,149	-13,089	-10,946	-9,888	-9,194	-8,797	-7,808	-7,046	-5,899	-4,049	-3,175	-2,789	-2,186	-1,807	-1,256	-659	1,269	1,772	1,195	-2,176	-2,452	-4,598	2,759	1,845	-5,779	-4,777	-11,986	-5,163	4,857	2,477	2,731	4,685	2,871	3,446	0	0	0
Loss per common share, basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	-0.04	-	-	-	-	-	-	-	-	-	-0.21	0.26	-0.16	-	-0.03	-0.02	0.11	-	-0.17	-0.01	-	0.08	-0.01
Basic net loss per common share
0.19	-	-0.09	-0.24	0.14	-	-0.14	-0.14	-0.09	-	-0.15	-0.11	-0.06	-	-0.04	-0.06	-0.04	-	-0.01	-0.02	0.02	-	0.04	-0.08	-0.33	-	-	-	-	-	-	-	-	-	-	-	0.23	-	-
Diluted net loss per common share
0.19	-	-0.09	-0.24	0.14	-	-0.14	-0.14	-0.09	-	-0.15	-0.11	-0.06	-	-0.04	-0.06	-0.04	-	-0.01	-0.02	0.01	-	0.03	-0.08	-0.33	-	-	-	-	-	-	-	-	-	-	-	0.19	-	-
Weighted-average number of common shares outstanding, basic
19,896	19,896	19,896	19,896	19,896	19,785	18,968	18,585	18,430	16,481	15,740	14,192	13,643	-	13,643	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average number of common shares outstanding, basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,813	10,942	10,944	10,929	10,830	10,605	-	9,861	9,846	9,769	-19,826	8,386	25,158	25,158	75,423	25,158	25	25	-63,712	18,085	25,158	20,565	20,461	368,294
Weighted-average number of common shares outstanding, diluted
19,896	-	19,896	19,896	19,896	-	18,968	18,585	18,430	-	15,740	14,192	13,643	-	13,643	12,813	10,942	9,679	10,929	10,830	11,870	-	11,154	9,846	9,769	-16,899	8,386	25,639	25,158	75,423	25,158	25	25	-68,147	18,085	25,158	25,001	20,461	368,294